Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Penicillamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.95 |
| ▸ | MAPT | P10636 | 2/20 | 0.95 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.36 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.32 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Penicillamine SCHEMBL1278140 | 1.00 | ALDH1A1 (0.95) | ALDH1A1PTGS1MAPTSLC7A5SLC7A11 | |
| Dl-Penicillamine SCHEMBL316497 | 1.00 | ALDH1A1 (0.95) | ALDH1A1PTGS1MAPTSLC7A5SLC7A11 | |
| Penicillamine SCHEMBL129296 | 0.97 | ALDH1A1 (1.00) | ALDH1A1PTGS1MAPTSLC7A5SLC7A11 | |
| Dl-Penicillamine SCHEMBL22322162 | 0.97 | ALDH1A1 (1.00) | ALDH1A1PTGS1MAPTSLC7A5SLC7A11 | |
| Dl-Penicillamine SCHEMBL4344 | 0.97 | — | — | |
| Penicillamine SCHEMBL4343 | 0.97 | — | — | |
| Dl-Penicillamine SCHEMBL57527 | 0.97 | — | — | |
| Penicillamine SCHEMBL603349 | 0.97 | ALDH1A1 (1.00) | ALDH1A1PTGS1MAPTSLC7A5SLC7A11 | |
| Dl-Penicillamine SCHEMBL159653 | 0.97 | ALDH1A1 (1.00) | ALDH1A1PTGS1MAPTSLC7A5SLC7A11 | |
| Penicillamine SCHEMBL6654084 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8679535-B2 | Sustained release matrix systems for highly soluble drugs | ENDO PHARMACEUTICALS INC. (US) | 2014-03-25 | — | — | US | claimed |
| US-4060548-A | Process of making penicillamine | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) | 1977-11-29 | — | — | US | claimed |
| US-3946069-A | Process of making penicillamine | DEUTSCHE GOLD-UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) | 1976-03-23 | — | — | US | claimed |
| US-20260027191-A1 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | UNIV ARIZONA (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4628100-A2 | ANTI-VIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF | Gregg, John Malcolm Hall (US) | 2025-10-08 | — | — | EP | disclosed |
| CN-119977889-A | Process method for preparing D-penicillamine by using acidic cationic resin | 上海药坦药物研究开发有限公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025093456-A1 | THIAZOLIDINE-4-CARBOXYLATE PROPERFUMES | FIRMENICH SA (CH) | 2025-05-08 | — | — | WO | disclosed |
| US-12285413-B2 | Anti-viral agents and methods for administration thereof | GREGG JOHN M H (US) | 2025-04-29 | — | — | US | disclosed |
| US-20250099566-A1 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | NATIONAL INSTITUTES OF HEALTH | 2025-03-27 | — | — | US | disclosed |
| CN-118834148-B | Preparation method of L-penicillamine | 天津凯莱英制药有限公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-118834148-A | Preparation method of L-penicillamine | 天津凯莱英制药有限公司 | 2024-10-25 | — | — | CN | disclosed |
| US-4060548-A | Process of making penicillamine | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) | 1977-11-29 | — | — | US | disclosed |
| US-4060548-A | Process of making penicillamine | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) | 1977-11-29 | — | — | US | disclosed |
| US-4045479-A | Process of preparing penicillamine | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) | 1977-08-30 | — | — | US | disclosed |
| US-3980665-A | Optically active salt of protected D-penicillamine and L-lysine | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) | 1976-09-14 | — | — | US | disclosed |
| US-3968154-A | Method of producing penicillamine | FIRMA HEYL & CO. CHEMISCH-PHARMAZEUTISCHE FABRIK (DT) | 1976-07-06 | — | — | US | disclosed |
| US-3954783-A | Resolution process and salt of protected D-penicillamine and L-pseudonorephedrine | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) | 1976-05-04 | — | — | US | disclosed |
| US-3948984-A | Process of making penicillamine | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) | 1976-04-06 | — | — | US | disclosed |
| US-3948984-A | Process of making penicillamine | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) | 1976-04-06 | — | — | US | disclosed |
| US-3946069-A | Process of making penicillamine | DEUTSCHE GOLD-UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) | 1976-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027191-A1 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | DNMT3L, DNMT3A, DNMT1 | PTGS1 3474/4885ALDH1A1 4602/4885MAPT 2164/4885 |
| US-12285413-B2 | Anti-viral agents and methods for administration thereof | ACE2, ACE, MAVS | PTGS1 597/4885ALDH1A1 4142/4885MAPT 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.